The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year

1999

About DiNonA

DiNonA is a biopharmaceutical development company that engages in the research, development, manufacture, and commercialization of antibody related therapeutics, medical devices, and diagnostic and research reagents. It provides antibody drugs; laser systems for use in beauty and cosmetic fields; medical devices that are used in women pregnancy and ovulation diagnosis; and smoke testing devices in general markets; as well as through internet malls.

DiNonA Headquarters Location

Asan Institute for Life Sciences 11th Floor 88 Olympic-ro 43-gil Songpa-gu

Seoul,

South Korea

+82 25780810

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

DiNonA Patents

DiNonA has filed 13 patents.

The 3 most popular patent topics include:

  • Clusters of differentiation
  • Immune system
  • Immunology
patents chart

Application Date

Grant Date

Title

Related Topics

Status

11/14/2017

1/11/2022

Clusters of differentiation, Monoclonal antibodies, Immunology, Immune system, Transcription factors

Grant

Application Date

11/14/2017

Grant Date

1/11/2022

Title

Related Topics

Clusters of differentiation, Monoclonal antibodies, Immunology, Immune system, Transcription factors

Status

Grant

Latest DiNonA News

Samsung, Dinona team up to develop COVID-19 antibody therapies

Oct 20, 2020

Samsung Biologics says the deal will fast-track the development of potential antibody treatment. Featured Incheon, South Korea-based Samsung Biologics, Samsung's biotech arm, said on Tuesday that the agreement will see both companies collaborate on the "fast-track development" of DNP-019, an agent currently being explored for COVID-19 treatments. Samsung's biological unit has expanded its Contract Development Organization (CDO) business quickly, with close to 60 contracts inked within the last two years. Under the Dinona CDO contract, Samsung will assist with cell line development, pharmaceutical process creation, and both clinical and non-clinical manufacturing and supply. "As with all our partnerships, we will closely collaborate with our client Dinona to provide the highest client satisfaction and support in its endeavor to bring a potential COVID-19 treatment to market faster and better," commented Tae Han Kim, CEO of Samsung Biologics. The news builds upon another partnership, announced in September, between Samsung Biologics and AstraZeneca, a biopharmaceutical organization currently working on a potential COVID-19 vaccine. The agreement, valued at $330.8 million , requires Samsung to provide commercial manufacturing resources at existing facilities, potentially ramping up production quickly should a vaccine be approved and distributed. If so, this long-term supply agreement may be worth up to $545 million.

  • When was DiNonA founded?

    DiNonA was founded in 1999.

  • Where is DiNonA's headquarters?

    DiNonA's headquarters is located at Asan Institute for Life Sciences 11th Floor, Seoul.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.